Browse SAMD4A

Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell projection, dendrite Cell junction, synapse, synaptosome Note=Enriched in synaptoneurosomes (By similarity). Shuttles between the nucleus and the cytoplasm in a CRM1-dependent manner. Colocalizes throughout the cytoplasm in granules with polyadenylated RNAs, PABPC1 and STAU1. Also frequently colocalizes in cytoplasmic stress granule-like foci with ELAVL1, TIA1 and TIAL1.
Domain PF00536 SAM domain (Sterile alpha motif)
Function

Acts as a translational repressor of SRE-containing messengers.

> Gene Ontology
 
Biological Process GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006417 regulation of translation
GO:0010608 posttranscriptional regulation of gene expression
GO:0017148 negative regulation of translation
GO:0019439 aromatic compound catabolic process
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0043487 regulation of RNA stability
GO:0043488 regulation of mRNA stability
GO:0044270 cellular nitrogen compound catabolic process
GO:0045727 positive regulation of translation
GO:0046700 heterocycle catabolic process
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0003729 mRNA binding
GO:0030371 translation repressor activity
GO:0045182 translation regulator activity
Cellular Component GO:0000932 cytoplasmic mRNA processing body
GO:0030425 dendrite
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SAMD4A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SAMD4A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SAMD4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3220.241
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3630.796
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2980.754
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2790.532
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5880.786
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1120.968
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3290.387
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2570.874
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0130.582
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1510.881
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1230.395
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4660.000428
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SAMD4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SAMD4A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SAMD4A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SAMD4A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SAMD4A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SAMD4A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SAMD4A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSAMD4A
Namesterile alpha motif domain containing 4A
Aliases KIAA1053; DKFZP434H0350; Smaug; SMGA; hSmaug1; smaug homolog (Drosophila); SAMD4; sterile alpha motif domain ......
Chromosomal Location14q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SAMD4A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.